Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.

Sarris J, Sinclair J, Karamacoska D, Davidson M, Firth J.

BMC Psychiatry. 2020 Jan 16;20(1):24. doi: 10.1186/s12888-019-2409-8.

2.

Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans.

Chadwick VL, Rohleder C, Koethe D, Leweke FM.

Curr Opin Psychiatry. 2020 Jan;33(1):20-42. doi: 10.1097/YCO.0000000000000562.

PMID:
31714262
3.

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.

Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L.

Lancet Psychiatry. 2019 Dec;6(12):995-1010. doi: 10.1016/S2215-0366(19)30401-8. Epub 2019 Oct 28. Erratum in: Lancet Psychiatry. 2020 Jan;7(1):e3.

PMID:
31672337
4.

Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report.

Bolsoni LM, da Silva TDA, Quintana SM, de Castro M, Crippa JA, Zuardi AW.

Perm J. 2019;23. doi: 10.7812/TPP/18.300. Epub 2019 Sep 27.

5.

Cannabidiol and the Remainder of the Plant Extract Modulate the Effects of Δ9-Tetrahydrocannabinol on Fear Memory Reconsolidation.

Murkar A, Kent P, Cayer C, James J, Durst T, Merali Z.

Front Behav Neurosci. 2019 Aug 1;13:174. doi: 10.3389/fnbeh.2019.00174. eCollection 2019.

6.

Cannabidiol (CBD) use in psychiatric disorders: A systematic review.

Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F.

Neurotoxicology. 2019 Sep;74:282-298. doi: 10.1016/j.neuro.2019.08.002. Epub 2019 Aug 11. Review.

PMID:
31412258
7.

Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms.

Casarett DJ, Beliveau JN, Arbus MS.

J Palliat Med. 2019 Oct;22(10):1180-1184. doi: 10.1089/jpm.2018.0658. Epub 2019 Aug 6.

8.

The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats.

Shallcross J, Hámor P, Bechard AR, Romano M, Knackstedt L, Schwendt M.

Front Behav Neurosci. 2019 May 10;13:91. doi: 10.3389/fnbeh.2019.00091. eCollection 2019.

9.

The use of cannabinoids for sleep: A critical review on clinical trials.

Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN.

Exp Clin Psychopharmacol. 2019 Aug;27(4):383-401. doi: 10.1037/pha0000285. Epub 2019 May 23.

PMID:
31120284
11.

Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies.

Lisboa SF, Vila-Verde C, Rosa J, Uliana DL, Stern CAJ, Bertoglio LJ, Resstel LB, Guimaraes FS.

Psychopharmacology (Berl). 2019 Jan;236(1):201-226. doi: 10.1007/s00213-018-5127-x. Epub 2019 Jan 2. Review.

PMID:
30604182
12.

Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.

Elms L, Shannon S, Hughes S, Lewis N.

J Altern Complement Med. 2019 Apr;25(4):392-397. doi: 10.1089/acm.2018.0437. Epub 2018 Dec 13.

13.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
14.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.

Crippa JA, Guimarães FS, Campos AC, Zuardi AW.

Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Review.

15.

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials.

Bitencourt RM, Takahashi RN.

Front Neurosci. 2018 Jul 24;12:502. doi: 10.3389/fnins.2018.00502. eCollection 2018. Review.

16.

Learning and memory is modulated by cannabidiol when administered during trace fear-conditioning.

Uhernik AL, Montoya ZT, Balkissoon CD, Smith JP.

Neurobiol Learn Mem. 2018 Mar;149:68-76. doi: 10.1016/j.nlm.2018.02.009. Epub 2018 Feb 9.

PMID:
29432803
17.

Training and Practices of Cannabis Dispensary Staff.

Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO.

Cannabis Cannabinoid Res. 2016 Dec 1;1(1):244-251. doi: 10.1089/can.2016.0024. eCollection 2016.

18.

The endocannabinoid system as a target for novel anxiolytic drugs.

Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A.

Neurosci Biobehav Rev. 2017 May;76(Pt A):56-66. doi: 10.1016/j.neubiorev.2016.12.033. Review.

19.

Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Babson KA, Sottile J, Morabito D.

Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9. Review.

PMID:
28349316
20.

Selective post-training time window for memory consolidation interference of cannabidiol into the prefrontal cortex: Reduced dopaminergic modulation and immediate gene expression in limbic circuits.

Rossignoli MT, Lopes-Aguiar C, Ruggiero RN, Do Val da Silva RA, Bueno-Junior LS, Kandratavicius L, Peixoto-Santos JE, Crippa JA, Cecilio Hallak JE, Zuardi AW, Szawka RE, Anselmo-Franci J, Leite JP, Romcy-Pereira RN.

Neuroscience. 2017 May 14;350:85-93. doi: 10.1016/j.neuroscience.2017.03.019. Epub 2017 Mar 24.

PMID:
28344069

Supplemental Content

Loading ...
Support Center